RadNet (NASDAQ:RDNT) & Daxor (NASDAQ:DXR) Head to Head Analysis

Daxor (NASDAQ:DXR) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Volatility & Risk

Daxor has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Insider & Institutional Ownership

1.3% of Daxor shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 59.5% of Daxor shares are held by insiders. Comparatively, 5.6% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Daxor and RadNet”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
RadNet	$1.83 billion	3.00	$2.79 million	($0.17)	-418.12

RadNet has higher revenue and earnings than Daxor.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Daxor and RadNet, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	1	2	0	2.67
RadNet	1	1	5	2	2.89

Daxor presently has a consensus price target of $25.00, suggesting a potential upside of 101.61%. RadNet has a consensus price target of $90.33, suggesting a potential upside of 27.09%. Given Daxor’s higher probable upside, equities research analysts plainly believe Daxor is more favorable than RadNet.

Profitability

This table compares Daxor and RadNet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
RadNet	-0.65%	2.52%	0.87%

Summary

RadNet beats Daxor on 8 of the 11 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.